Literature DB >> 19079069

Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.

Linda P Dwoskin1, Michael T Bardo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19079069      PMCID： PMC3089967          DOI： 10.1038/npp.2008.157

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  7 in total

1.  Targeted in vivo expression of nicotinic acetylcholine receptors in mouse brain using lentiviral expression vectors.

Authors:  B E Molles; U Maskos; S Pons; M Besson; P Guiard; J-P Guilloux; A Evrard; A Cormier; M Mameli-Engvall; I Cloëz-Tayarani; H Nakatani; N Dufour; A-P Bemelmans; J Mallet; P Cazala; A M Gardier; V David; P Faure; S Granon; J-P Changeux
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

2.  Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats.

Authors:  N M Neugebauer; Z Zhang; P A Crooks; L P Dwoskin; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

3.  The effects of a novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens.

Authors:  Shafiqur Rahman; Nichole M Neugebauer; Z Zhang; Peter A Crooks; Linda P Dwoskin; Michael T Bardo
Journal:  Neuropharmacology       Date:  2006-11-09       Impact factor: 5.250

4.  Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.

Authors:  Linda P Dwoskin; Sangeetha P Sumithran; Jun Zhu; A Gabriela Deaciuc; Joshua T Ayers; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

5.  Pharmacokinetics of the novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat.

Authors:  Zaineb A Fadhel Albayati; Linda P Dwoskin; Peter A Crooks
Journal:  Drug Metab Dispos       Date:  2008-07-10       Impact factor: 3.922

6.  N,N'-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-evoked dopamine release and hyperactivity.

Authors:  Linda P Dwoskin; Thomas E Wooters; Sangeetha P Sumithran; Kiran B Siripurapu; B Matthew Joyce; Paul R Lockman; Vamshi K Manda; Joshua T Ayers; Zhenfa Zhang; Agripina G Deaciuc; J Michael McIntosh; Peter A Crooks; Michael T Bardo
Journal:  J Pharmacol Exp Ther       Date:  2008-05-06       Impact factor: 4.030

7.  Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.

Authors:  Linda P Dwoskin; Marharyta Pivavarchyk; B Matthew Joyce; Nichole M Neugebauer; Guangrong Zheng; Zhenfa Zhang; Michael T Bardo; Peter A Crooks
Journal:  Nebr Symp Motiv       Date:  2009
  7 in total
  11 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine release.

Authors:  Marharyta Pivavarchyk; Andrew M Smith; Zhenfa Zhang; Dejun Zhou; Xu Wang; Naoki Toyooka; Hiroshi Tsuneki; Toshiyasu Sasaoka; J Michael McIntosh; Peter A Crooks; Linda P Dwoskin
Journal:  Eur J Pharmacol       Date:  2011-03-01       Impact factor: 4.432

3.  bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.

Authors:  Thomas E Wooters; Andrew M Smith; Marharyta Pivavarchyk; Kiran B Siripurapu; J Michael McIntosh; Zhenfa Zhang; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 4.  The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.

Authors:  Hans Rollema; Raymond S Hurst
Journal:  Psychopharmacology (Berl)       Date:  2018-07-07       Impact factor: 4.530

Review 5.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

6.  Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.

Authors:  Tanuja Bordia; Maya Hrachova; Matthew Chin; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2012-05-01       Impact factor: 4.030

7.  Structure and activity of alpha-conotoxin PeIA at nicotinic acetylcholine receptor subtypes and GABA(B) receptor-coupled N-type calcium channels.

Authors:  Norelle L Daly; Brid Callaghan; Richard J Clark; Simon T Nevin; David J Adams; David J Craik
Journal:  J Biol Chem       Date:  2011-01-20       Impact factor: 5.157

8.  Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.

Authors:  Guangrong Zheng; Zhenfa Zhang; Paul R Lockman; Werner J Geldenhuys; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

Review 9.  Potential therapeutic uses of mecamylamine and its stereoisomers.

Authors:  Justin R Nickell; Vladimir P Grinevich; Kiran B Siripurapu; Andrew M Smith; Linda P Dwoskin
Journal:  Pharmacol Biochem Behav       Date:  2013-04-18       Impact factor: 3.533

Review 10.  Alpha9 nicotinic acetylcholine receptors and the treatment of pain.

Authors:  J Michael McIntosh; Nathan Absalom; Mary Chebib; Ana Belén Elgoyhen; Michelle Vincler
Journal:  Biochem Pharmacol       Date:  2009-05-27       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.